PapersSelected

ImmuneAgent AI System Discovers Broadly Neutralizing Antibodies Across Virus Families

Multimodal reasoning for broadly neutralizing antibody discovery from label-free human B cell repertoires across virus families

Why we picked it

The wet-lab feedback loop is what separates this from prior sequence-based predictors: discovery rates are validated experimentally at a fixed cloning budget, not just benchmarked in silico. Immunology researchers and biotech teams working on antibody therapeutics can use the framework to target emerging pathogens without antigen-specific sorting. The 11% bnAb yield sets a concrete bar against existing cofolding models for anyone planning screening campaigns.

Researchers present ImmuneAgent, a closed-loop AI system combining multimodal reasoning, continual meta-learning and wet-lab feedback to find broadly neutralizing antibodies (bnAbs) in human B cell repertoires.

Body

Screening repertoires from vaccinated or infected cohorts, it achieved a ~55% neutralization antibody discovery rate, with 60 of 110 cloned candidates neutralizing, and a ~11% bnAb yield (12 of 110).

Five discovered antibodies conferred 100% in vivo protection against lethal influenza challenge, comparable to clinical-stage therapeutic MEDI8852.

The system also identified FCRL5+CD27+ atypical memory B cells as a conserved bnAb reservoir and discovered human metapneumovirus cross-neutralizing and HPV-neutralizing antibodies without antigen-specific sorting.

Original · arXiv cs.AI

Multimodal reasoning for broadly neutralizing antibody discovery from label-free human B cell repertoires across virus families

Discovering broadly neutralizing antibodies (bnAbs) from human natural immune repertoires remains a fundamental challenge in immunology, hindered by: the extreme rarity of bnAb, incomplete understanding of their cellular origins across pathogens, and the inability of existing computational tools to generalize across emerging viral threats. Here we present ImmuneAgent, a closed-loop AI system that integrates multimodal reasoning with continual meta-learning and wet-lab feedback to overcome these barriers. Applied to screen the natural BCR repertoires from vaccinated or infected cohorts, the system achieves a ~55% neutralization antibody discovery rate (60 of 110 cloned candidates) and a ~11% bnAb yield (12 of 110), substantially outperforming a state-of-the-art sequence-based neutralization predictor or cofolding models evaluated at the same cloning budget. Five ImmuneAgent-discovered antibodies conferred 100% in vivo protection against lethal influenza challenge, comparable to the clinical-stage therapeutic MEDI8852. The system recovered the cellular and structural determinants of bnAb activity and identified FCRL5+CD27+ atypical memory B cells as a conserved bnAb reservoir and hydrophobic interface enrichment as a cross-viral structural signature, which generalized to unseen antigens, discovering human metapneumovirus (hMPV) cross-neutralizing and human papillomavirus (HPV)-neutralizing antibodies without antigen-specific sorting. These results validate that ImmuneAgent is a generalizable framework for rapid therapeutic antibody discovery against emerging viral threats.

Industry Coordinates & Source Verification

This report is categorized under AITOP's "Papers" desk, focusing on US frontier AI labs and Silicon Valley technology leaders. Within our cross-regional analytical framework, it directly maps to AI developer toolchains, coding agents, and engineering workflows. Key entities and technical topics under continuous tracking include ImmuneAgent, multimodal, AI drug discovery, meta-learning.

Source attribution: curated from arXiv cs.AI (@Hantao Lou, Jianqing Zheng, Can Yue, Meihan Zhang, Yuanchao Bao, Yu Chen, Mengting Huang, Yupeng Yang, Qianyu Pan, Nana Fu, Yansong Shi, Hongli Li, Yangyang Chai, Ruyi Chen, Wansheng Li, Zhu Liang, Rongmei Yao, Yuanhan Mo, Lei Wang, Chunmei Wang, Yun Quan, Qiong Zhang, Xiangxi Wang, Xuetao Cao).